Death receptors as targets in cancer

Abstract : Anti-tumour therapies based on the use PARAs (pro-apoptotic receptor agonists), including TRAIL (TNF-Related Apoptosis inducing Ligand) or monoclonal antibodies targeting TRAIL-R1 or TRAIL-R2, have been disappointing so far, despite clear evidence of clinical activity and lack of adverse events for the vast majority of these compounds, whether combined or not with conventional or targeted anti-cancer therapies. This brief review aims at discussing the possible reasons for the lack of apparent success of these therapeutic approaches and at providing hints in order to rationally design optimal protocols based on our current understanding of TRAIL signalling regulation or resistance for future clinical trials.
Type de document :
Pré-publication, Document de travail
2014
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00823459
Contributeur : Olivier Micheau <>
Soumis le : jeudi 1 mai 2014 - 07:00:03
Dernière modification le : vendredi 8 juin 2018 - 14:50:12
Document(s) archivé(s) le : jeudi 31 juillet 2014 - 10:35:51

Fichiers

Figures_Micheau.pdf
Fichiers produits par l'(les) auteur(s)

Identifiants

  • HAL Id : inserm-00823459, version 1

Collections

Citation

Olivier Micheau, Sarah Shirley, Florent Dufour. Death receptors as targets in cancer. 2014. 〈inserm-00823459〉

Partager

Métriques

Consultations de la notice

2441

Téléchargements de fichiers

580